What is Biorelate?
Biorelate specializes in advanced data curation technology designed specifically for the biopharmaceutical sector. Its flagship platform, Galactic AI, functions as a sophisticated knowledge graph that synthesizes causal insights from disparate data sources. This technology empowers bioinformatics professionals to identify and validate novel drug targets, elucidate mechanisms of action, and map intricate target-drug-disease relationships. By serving a diverse clientele ranging from multinational pharmaceutical giants to agile biotech innovators, Biorelate has established itself as a critical infrastructure provider in the drug development ecosystem. The platform effectively streamlines the research process, enabling faster, data-driven decision-making in high-stakes therapeutic development environments.
How much funding has Biorelate raised?
Biorelate has raised a total of $6.5M across 1 funding round:
Series A
$6.5M
Series A (2022): $6.5M with participation from Manchester Technology Fund, Triple Point Ventures, YFM Equity Partners, and Maven Capital Partners UK
Key Investors in Biorelate
Manchester Technology Fund
A specialized investment vehicle focused on early-stage equity for university spin-outs, backed by the UK Government and the Wellcome Trust.
Triple Point Ventures
A venture firm targeting B2B software startups, with a specific focus on AI, healthcare, and data-driven business models.
YFM Equity Partners
An independent private equity firm providing growth capital and entrepreneurial coaching to support the development of emerging business projects.
What's next for Biorelate?
With the recent capital injection, Biorelate is poised to accelerate the development of its Galactic AI platform, focusing on expanding its data ingestion capabilities and enhancing the predictive accuracy of its knowledge graphs. The strategic roadmap likely includes scaling its enterprise sales force to capture a larger share of the global pharmaceutical market and deepening its integration with existing R&D workflows. As the industry continues to prioritize AI-driven discovery, Biorelate is strategically positioned to capitalize on the increasing demand for high-fidelity, curated biological data. Future growth will likely center on forming deeper partnerships with global research institutions and expanding the platform's utility across diverse therapeutic areas, ensuring that the company remains at the forefront of the digital transformation in life sciences.
See full Biorelate company page
